Latest Nasdaq News

Metallium has completed a 12-hour campaign using three Flash Joule Heating reactors to process platinum-group-metal-bearing catalytic converter material under reactive chlorination conditions. The milestone advances the company’s scale-up program, but recovery results, product economics and feedstock grades remain unverified.

Aurora Energy Metals (ASX:1AE) swung to a $21.8 million profit after selling its Oregon uranium project, but the result was driven largely by a non-cash accounting gain. The company’s concentrated Eagle Nuclear Energy stake was valued at about $15.5 million by the annual report date, down from $23.9 million at 30 June.

Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.

European Lithium reported a A$930.6 million FY2026 profit, but the headline result was dominated by a A$1.276 billion accounting gain after losing control of Critical Metals Corp. The company now heads towards an October vote on a merger that would fold its cash, CRML stake and mineral assets into a single NASDAQ-listed group.

Resolution Minerals has turned Horse Heaven into the centre of its strategy, pairing broad gold drilling with high-grade antimony and tungsten test work. The expansion came with a sharply higher A$53.3 million FY2026 loss and a disclosed dependence on future funding.

Telix has secured FDA Fast Track designation for BiPASS, its Phase 3 program testing 68Ga-PSMA-PET alongside MRI before prostate biopsy. The milestone may support closer FDA engagement and faster review of a planned NDA, but the indication remains investigational and no BiPASS results were disclosed.

Jindalee Lithium has advanced its proposed US Elemental Nasdaq listing and prepared to launch major drilling at McDermitt, but its audited FY26 accounts flag a material uncertainty over ongoing funding. The company ended June with A$13.6 million in cash after raising about A$20.4 million, while reporting a A$7.2 million loss and no operating revenue.

Neuren says its partner Acadia has received a US Notice of Allowance for a trofinetide patent that could protect weight-banded dosing through 28 March 2041. The patent has not yet formally issued, but the allowance could extend US protection by almost five years beyond the existing method-of-use patent.

Global X Ultra Short Nasdaq 100 Complex ETF (ASX:SNAS) reported a $40.982 million loss for the year ended 30 June 2026, more than twice the prior year’s loss. Net assets still rose to $55.278 million as new applications outpaced redemptions, highlighting the difference between fund size and investor returns.

Global X Nasdaq 100 Covered Call Complex ETF reported a sharp improvement in annual profit, helped by a swing to fair-value gains and continued investor applications. The ASX-listed feeder fund paid or accrued $2.731 million in distributions, but the result does not show whether investors achieved a positive total return after unit-price movements.

Global X Ultra Long Nasdaq 100 Complex ETF delivered a sharply higher annual profit, driven largely by realised gains, but its net asset value has since fallen more than 10%. The result highlights both the attraction and the volatility of geared exposure to the Nasdaq 100.

American Tungsten & Antimony has submitted a confidential draft Form F-1 to US regulators, moving its proposed Level III ADR listing on Nasdaq into formal review. The company also extended the Del Sol transaction end date by three weeks, leaving both major initiatives progressing but unfinished.